See more : Vintage Securities Limited (VINTAGES.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Rhythm Biosciences Limited (RHY.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rhythm Biosciences Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- TransAlta Corp (TSLTF) Income Statement Analysis – Financial Results
- Zeons Corporation (ZEON) Income Statement Analysis – Financial Results
- Canadian Banc Corp. (CNDCF) Income Statement Analysis – Financial Results
- Lightning eMotors, Inc. (ZEVY) Income Statement Analysis – Financial Results
- Salam International Investment Limited Q.P.S.C. (SIIS.QA) Income Statement Analysis – Financial Results
Rhythm Biosciences Limited (RHY.AX)
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.69M | 3.10M | 2.43M | 1.11M | 100.00K | 1.03M | 0.00 | 0.00 |
| Cost of Revenue | 3.05M | 189.38K | 101.48K | 146.65K | 141.29K | 65.37K | 31.54K | 0.00 |
| Gross Profit | -1.36M | 2.91M | 2.33M | 961.86K | -41.29K | 962.25K | -31.54K | 0.00 |
| Gross Profit Ratio | -80.31% | 93.88% | 95.82% | 86.77% | -41.29% | 93.64% | 0.00% | 0.00% |
| Research & Development | 2.35M | 3.65M | 5.16M | 4.55M | 1.94M | 980.28K | 359.11K | 299.52K |
| General & Administrative | 1.22M | 7.33M | 5.33M | 2.97M | 2.00M | 2.28M | 1.13M | 422.00K |
| Selling & Marketing | 115.50K | 175.56K | 561.86K | 62.82K | 41.85K | 302.93K | 93.48K | -349.88K |
| SG&A | 3.00M | 7.51M | 5.90M | 3.03M | 2.04M | 2.58M | 1.22M | 72.13K |
| Other Expenses | 0.00 | 3.10M | 191.56K | 150.37K | 182.84K | 154.33K | -189.32K | 0.00 |
| Operating Expenses | 5.35M | 11.54M | 11.25M | 7.73M | 4.16M | 3.71M | 1.63M | 72.13K |
| Cost & Expenses | 8.40M | 11.54M | 11.25M | 7.73M | 4.16M | 3.71M | 1.63M | 72.13K |
| Interest Income | 52.28K | 228.27K | 24.97K | 13.97K | 46.27K | 141.07K | 64.48K | 0.00 |
| Interest Expense | 3.14K | 0.00 | 24.97K | 396.00 | 7.80K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 110.01K | 189.38K | 101.48K | 146.65K | 141.29K | 65.37K | 31.54K | 805.52K |
| EBITDA | -6.80M | -11.11M | -11.10M | -6.47M | -3.87M | -2.61M | -1.60M | 733.40K |
| EBITDA Ratio | -402.09% | -366.69% | -459.11% | -583.23% | -3,873.90% | -355.14% | 0.00% | 0.00% |
| Operating Income | -6.71M | -11.54M | -11.25M | -6.61M | -4.02M | -3.71M | -1.63M | -72.13K |
| Operating Income Ratio | -396.84% | -372.81% | -463.29% | -596.46% | -4,015.19% | -361.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.84M | 3.32M | 2.45M | -133.86K | -102.82K | 1.17M | -156.38K | -60.00K |
| Income Before Tax | -8.55M | -8.22M | -8.79M | -6.61M | -4.02M | -2.55M | -1.75M | -72.13K |
| Income Before Tax Ratio | -505.69% | -265.44% | -362.26% | -596.49% | -4,022.98% | -247.77% | 0.00% | 0.00% |
| Income Tax Expense | -1.69M | -228.27K | -2.48M | 1.11M | 107.80K | -1.17M | 124.85K | -805.52K |
| Net Income | -6.86M | -8.22M | -6.32M | -7.72M | -4.13M | -1.38M | -1.75M | -72.13K |
| Net Income Ratio | -405.69% | -265.44% | -260.20% | -696.53% | -4,130.78% | -134.05% | 0.00% | 0.00% |
| EPS | -0.03 | -0.04 | -0.03 | -0.04 | -0.04 | -0.01 | -0.02 | 0.00 |
| EPS Diluted | -0.03 | -0.04 | -0.03 | -0.04 | -0.04 | -0.01 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 228.30M | 221.54M | 214.45M | 189.95M | 117.93M | 117.93M | 89.29M | 117.93M |
| Weighted Avg Shares Out (Dil) | 228.30M | 221.54M | 214.45M | 189.95M | 117.93M | 117.93M | 89.29M | 117.93M |
Source: https://incomestatements.info
Category: Stock Reports